A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Summary

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.

Timeline

Start

2026-06-11

Primary completion

2028-09-14

Completion

2028-09-14

Drugs

Indications